BioXcel Therapeutics (BTAI) Income from Continuing Operations (2017 - 2026)

BioXcel Therapeutics' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 14210000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 2.87% year-over-year to 14210000.0 in Q1 2026; TTM through Mar 2026 was 66335000.0, a 10.84% decrease from a year earlier, with the FY2025 full-year figure at 66379000.0, up 74.15% from the prior year.
• Income from Continuing Operations rose to 14210000.0 in Q1 2026 per BTAI's latest filing, from 14357000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 7241000.0 in Q4 2024 and bottomed at 169781000.0 in Q4 2022.
• The 5-year median for Income from Continuing Operations is 22057000.0 (2023), against an average of 43593352.94.
• Across the five-year window, Income from Continuing Operations plunged 549.88% in 2022 and soared 87.01% in 2023, its largest moves.
• Year by year, Income from Continuing Operations stood at 169781000.0 in 2022, then surged by 87.01% to 22057000.0 in 2023, then surged by 67.17% to 7241000.0 in 2024, then sank by 98.27% to 14357000.0 in 2025, then gained by 1.02% to 14210000.0 in 2026.
• Per Business Quant, the three latest BTAI Income from Continuing Operations figures stand at 14210000.0 (Q1 2026), 14357000.0 (Q4 2025), and 17924000.0 (Q3 2025).